Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
6138 | 1524 | 39.4 | 78% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
370 | 3 | ACUTE PANCREATITIS//PANCREATIC CANCER//CHRONIC PANCREATITIS | 33394 |
217 | 2 | PANCREATIC CANCER//CHRONIC PANCREATITIS//PANCREATICODUODENECTOMY | 20665 |
6138 | 1 | PANCREATIC CANCER//GEMCITABINE//ADVANCED PANCREATIC CANCER | 1524 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PANCREATIC CANCER | authKW | 1031672 | 45% | 7% | 691 |
2 | GEMCITABINE | authKW | 889520 | 27% | 11% | 418 |
3 | ADVANCED PANCREATIC CANCER | authKW | 534546 | 3% | 65% | 41 |
4 | METASTATIC PANCREATIC CANCER | authKW | 469577 | 2% | 76% | 31 |
5 | FOLFIRINOX | authKW | 423196 | 3% | 54% | 39 |
6 | NAB PACLITAXEL | authKW | 189136 | 3% | 21% | 44 |
7 | GEMCITABINE REFRACTORY | authKW | 166952 | 1% | 83% | 10 |
8 | ADVANCED PANCREATIC CARCINOMA | authKW | 142592 | 1% | 65% | 11 |
9 | PANCREATIC CARCINOMA | authKW | 77911 | 4% | 6% | 62 |
10 | HEPATOBILIARY PANCREAT ONCOL | address | 77654 | 2% | 12% | 32 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 27597 | 69% | 0% | 1045 |
2 | Gastroenterology & Hepatology | 3362 | 15% | 0% | 225 |
3 | Pharmacology & Pharmacy | 589 | 14% | 0% | 210 |
4 | Surgery | 176 | 8% | 0% | 122 |
5 | Medicine, General & Internal | 20 | 4% | 0% | 54 |
6 | Medicine, Research & Experimental | 9 | 2% | 0% | 33 |
7 | Integrative & Complementary Medicine | 0 | 0% | 0% | 3 |
8 | Hematology | 0 | 1% | 0% | 15 |
9 | Radiology, Nuclear Medicine & Medical Imaging | 0 | 2% | 0% | 23 |
10 | Geriatrics & Gerontology | 0 | 0% | 0% | 5 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HEPATOBILIARY PANCREAT ONCOL | 77654 | 2% | 12% | 32 |
2 | HEPATOBILIARY PANCREAT MED ONCOL | 61541 | 1% | 24% | 13 |
3 | IRCCS S MATTEO UNIV HOSP FDN | 40069 | 0% | 100% | 2 |
4 | MED KLIN POLIKLIN MS HAMATOL ONKOL | 40065 | 0% | 50% | 4 |
5 | ABT CHIRURG ONKOL | 26712 | 0% | 67% | 2 |
6 | LANGONE ARENA ONCOL | 26712 | 0% | 67% | 2 |
7 | ADEBIOPHARM | 20035 | 0% | 100% | 1 |
8 | ALLIANCE DEV | 20035 | 0% | 100% | 1 |
9 | ANESTHESIOL SURG EMERGENCY SCI SURG ON | 20035 | 0% | 100% | 1 |
10 | AOU MATERDOMINI CATANZARO | 20035 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANNALS OF ONCOLOGY | 13271 | 5% | 1% | 74 |
2 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 12927 | 5% | 1% | 69 |
3 | ONCOLOGY | 8513 | 3% | 1% | 41 |
4 | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 8303 | 3% | 1% | 41 |
5 | INVESTIGATIONAL NEW DRUGS | 7992 | 2% | 1% | 32 |
6 | PANCREAS | 7566 | 3% | 1% | 39 |
7 | PANCREATOLOGY | 7159 | 1% | 2% | 21 |
8 | JOURNAL OF CLINICAL ONCOLOGY | 4376 | 4% | 0% | 60 |
9 | BRITISH JOURNAL OF CANCER | 3688 | 4% | 0% | 58 |
10 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 3469 | 0% | 3% | 5 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PANCREATIC CANCER | 1031672 | 45% | 7% | 691 | Search PANCREATIC+CANCER | Search PANCREATIC+CANCER |
2 | GEMCITABINE | 889520 | 27% | 11% | 418 | Search GEMCITABINE | Search GEMCITABINE |
3 | ADVANCED PANCREATIC CANCER | 534546 | 3% | 65% | 41 | Search ADVANCED+PANCREATIC+CANCER | Search ADVANCED+PANCREATIC+CANCER |
4 | METASTATIC PANCREATIC CANCER | 469577 | 2% | 76% | 31 | Search METASTATIC+PANCREATIC+CANCER | Search METASTATIC+PANCREATIC+CANCER |
5 | FOLFIRINOX | 423196 | 3% | 54% | 39 | Search FOLFIRINOX | Search FOLFIRINOX |
6 | NAB PACLITAXEL | 189136 | 3% | 21% | 44 | Search NAB+PACLITAXEL | Search NAB+PACLITAXEL |
7 | GEMCITABINE REFRACTORY | 166952 | 1% | 83% | 10 | Search GEMCITABINE+REFRACTORY | Search GEMCITABINE+REFRACTORY |
8 | ADVANCED PANCREATIC CARCINOMA | 142592 | 1% | 65% | 11 | Search ADVANCED+PANCREATIC+CARCINOMA | Search ADVANCED+PANCREATIC+CARCINOMA |
9 | PANCREATIC CARCINOMA | 77911 | 4% | 6% | 62 | Search PANCREATIC+CARCINOMA | Search PANCREATIC+CARCINOMA |
10 | MPACT | 71549 | 0% | 71% | 5 | Search MPACT | Search MPACT |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DI MARCO, M , DI CICILIA, R , MACCHINI, M , NOBILI, E , VECCHIARELLI, S , BRANDI, G , BIASCO, G , (2010) METASTATIC PANCREATIC CANCER: IS GEMCITABINE STILL THE BEST STANDARD TREATMENT? (REVIEW).ONCOLOGY REPORTS. VOL. 23. ISSUE 5. P. 1183-1192 | 83 | 90% | 63 |
2 | WALKER, EJ , KO, AH , (2014) BEYOND FIRST-LINE CHEMOTHERAPY FOR ADVANCED PANCREATIC CANCER: AN EXPANDING ARRAY OF THERAPEUTIC OPTIONS?.WORLD JOURNAL OF GASTROENTEROLOGY. VOL. 20. ISSUE 9. P. 2224 -2236 | 71 | 85% | 15 |
3 | KIM, EJ , SEMRAD, TJ , BOLD, RJ , (2015) PHASE II CLINICAL TRIALS ON INVESTIGATIONAL DRUGS FOR THE TREATMENT OF PANCREATIC CANCERS.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 24. ISSUE 6. P. 781 -794 | 77 | 81% | 1 |
4 | NAGRIAL, AM , CHIN, VT , SJOQUIST, KM , PAJIC, M , HORVATH, LG , BIANKIN, AV , YIP, D , (2015) SECOND-LINE TREATMENT IN INOPERABLE PANCREATIC ADENOCARCINOMA: A SYSTEMATIC REVIEW AND SYNTHESIS OF ALL CLINICAL TRIALS.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. VOL. 96. ISSUE 3. P. 483 -497 | 66 | 87% | 1 |
5 | RAHIB, L , FLESHMAN, JM , MATRISIAN, LM , BERLIN, JD , (2016) EVALUATION OF PANCREATIC CANCER CLINICAL TRIALS AND BENCHMARKS FOR CLINICALLY MEANINGFUL FUTURE TRIALS A SYSTEMATIC REVIEW.JAMA ONCOLOGY. VOL. 2. ISSUE 9. P. 1209 -1216 | 62 | 89% | 0 |
6 | COLLINS, DC , MORRIS, PG , (2015) SYSTEMIC THERAPY FOR ADVANCED PANCREATIC CANCER: INDIVIDUALISING CYTOTOXIC THERAPY.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 16. ISSUE 6. P. 851 -861 | 51 | 91% | 2 |
7 | WANG-GILLAM, A , LI, CP , BODOKY, G , DEAN, A , SHAN, YS , JAMESON, G , MACARULLA, T , LEE, KH , CUNNINGHAM, D , BLANC, JF , ET AL (2016) NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY (NAPOLI-1): A GLOBAL, RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL.LANCET. VOL. 387. ISSUE 10018. P. 545 -557 | 21 | 88% | 31 |
8 | CHUA, YJ , CUNNINGHAM, D , (2006) CHEMOTHERAPY FOR ADVANCED PANCREATIC CANCER.BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY. VOL. 20. ISSUE 2. P. 327-348 | 67 | 84% | 17 |
9 | XIONG, HQ , CARR, K , ABBRUZZESE, JL , (2006) CYTOTOXIC CHEMOTHERAPY FOR PANCREATIC CANCER - ADVANCES TO DATE AND FUTURE DIRECTIONS.DRUGS. VOL. 66. ISSUE 8. P. 1059 -1072 | 59 | 92% | 29 |
10 | THOTA, R , MAITRA, A , BERLIN, JD , (2017) PRECLINICAL RATIONALE FOR THE PHASE III TRIALS IN METASTATIC PANCREATIC CANCER IS WISHFUL THINKING CLOUDING SUCCESSFUL DRUG DEVELOPMENT FOR PANCREATIC CANCER?.PANCREAS. VOL. 46. ISSUE 2. P. 143 -150 | 62 | 68% | 0 |
Classes with closest relation at Level 1 |